Overview
Healthcare tech firm's Q4 revenue stable at $32.2 mln, beating analyst expectations
Adjusted EBITDA for Q4 hit record $12 mln, exceeding analyst estimates
Company authorized $10 mln share repurchase program
Outlook
Company updates 2026 revenue guidance to $109-$114 mln
Company expects 2026 adjusted EBITDA between $21 mln and $25 mln
Result Drivers
GROSS PROFIT INCREASE - Q4 gross profit rose 9% year-over-year to $24.1 mln, indicating improved operational efficiency
RULE OF 40 ACHIEVEMENT - Co achieved Rule of 40 benchmark in 2025, reflecting balance of growth and profitability
Company press release: ID:nGNX2RN9FD
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $32.2 mln | $31.10 mln (6 Analysts) |
Q4 Adjusted Net Income | Beat | $9.9 mln | $4.28 mln (5 Analysts) |
Q4 Adjusted EBITDA | Beat | $12 mln | $5.72 mln (6 Analysts) |
Q4 Gross Profit | $24.1 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the online services peer group is "buy"
Wall Street's median 12-month price target for OptimizeRx Corp is $24.00, about 205% above its March 4 closing price of $7.87
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 18 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments